Laurus Labs share price target 2023, 2024, 2025, and 2030: In this article, you will learn about Laurus Labs share price target 2023, 2024, 2025, and 2030, along with the fundamentals and financials of the company.
For every investor, it is important to know about the company in which they are investing, to get the confidence to hold the stock for the long term. To make it clear for you, in this article we have mentioned Laurus Labs share price target 2023, 2024, 2025, and 2030, along with the fundamentals of the company.
Also read: RBL Bank share price target.
Laurus Labs Share Price Target 2023, 2024, 2025, and 2030: Company Profile
Laurus Labs develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. Laurus Labs works with all the top 10 generic pharmaceutical companies in the world. Laurus Labs sell its APIs in 56 countries. Laurus Labs major focus areas include anti-retroviral, Hepatitis C, and Oncology drugs.
Continuous innovation is the lifeblood of its business. Therefore, Laurus Labs undertake dedicated R&D in areas that have significant growth potential. The company has filed 296 patents of which it owns 155 patents. Laurus Labs has commercialized 60+ products since inception across three distinct business units: Generics API, Generics FDF, and Synthesis.
Laurus Labs state-of-the-art research labs enable it to produce new cures to some of the most challenging diseases. With its manufacturing facilities, the company has cracked the code of creating high-quality and affordable medicines. Laurus Labs facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA, and BfArM. Laurus Labs strong R&D and API manufacturing capabilities are enabling the company to grow rapidly. The company is also one of the most admired companies to work for in the pharmaceutical and biotechnology sector.
Also read: Alok industries share price target.
Laurus Labs Share Price Target 2023
Laurus Labs leveraged its strong backward integration and demonstrated commendable execution capability in the formulation segment, growing 165x from 5 crores to 825 crores from 2018-19 to 2020-21. The majority growth came from tender-driven opportunities via participation in global funds, PEPFAR, and various in-country African tenders.
To scale up this segment and cater to new players, Laurus Labs plans to double the capacity to 10 billion units per annum over the next 18 months. Growth in APIs has been strong with the launch of first-line products. Other APIs (anti-diabetic, CNS, and PPI) are expected to be key growth drivers due to a robust order book and large capacity addition by the end of next year.
With a dedicated R&D center and manufacturing units, Laurus Labs is well-positioned to meet the rising demand for NCE drug substances and drug products. Laurus Labs is in the process of setting up a dedicated R&D centre and greenfield manufacturing capacity for Laurus Synthesis Private Limited to support future growth.
In order to supplement future growth, Capex plans are already underway to increase capacity by 1.8x by 2022. Laurus Labs is also developing a robust generic pipeline for the developed markets. The company has entered a partnership with a European generic player for contract manufacturing. To scale up this segment and cater to other players, the company plans to double the capacity to 10 billion units per annum over the next 18 months. By considering all the opportunities to grow its business in the future, Laurus Labs share price target for 2023 is Rs 410.
|Laurus Labs share price target 2023|
Also read: NBCC share price target.
Laurus Labs Share Price Target 2024
During the year, Laurus Labs has acquired a 72.55% stake in Richcore Lifesciences from two private equity funds, Eight Roads and Ventureast. The acquisition is aimed at diversifying and entering high-growth areas of recombinant animal origin-free products, enzymes as well as building biologics to CDMO at scale. The company has been renamed as Laurus Bio Private Limited and the current promoters will continue to be on the executive board and run the day-to-day management of the Company.
Laurus Labs is on a course of commissioning large-scale fermentation capability. Laurus Labs is also planning to acquire additional land for further expansion by creating close to million liters of fermentation capacity.
All four businesses have a robust growth outlook driven by improving demand and supported by capacity expansion plans lined up. Laurus Labs are enhancing their current portfolio, stepping up R&D activity, and strengthening and expanding manufacturing capabilities. The synthesis business is expected to stage strong growth over the next 2 years with sustained new client additions.
Laurus Bio is also expected to grow substantially over the next 4-5 years and would make us a fully integrated player in the pharmaceutical and biotechnology space. As both synthesis and Laurus Bio business has exceptional growth opportunities over the next 3 to 4 years, Laurus Labs share price target for 2024 is Rs 620.
|Laurus Labs share price target 2024|
Also read: GTL Infra share price target.
Laurus Labs Share Price Target 2025
According to Grand View Research, the global pharmaceutical manufacturing market size was valued at US$ 324.42 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 13.74% from 2020-27. One dominant trend seen by the global pharmaceutical industry is the increased use of medicines over the past decade, which has seen the rate of medicine usage outpace both population and economic growth.
This expansion has been largely on account of the growing pharmerging markets, where a growing number of patients now have improved access to treatment options. According to the IQVIA Institute of Human Data Science study, the global medicine market, using invoice price levels is expected to grow at 3-6% CAGR through 2025.
- The total cumulative spending on COVID-19 vaccines through 2025 is projected to be US$ 157 billion
- Global medicine spending will be lifted by stronger pharmerging market growth through 2025; it will be offset by slower growth in the developed markets because of loss of exclusivity for original brands
- Savings from biosimilars will reach an estimated US$ 285 billion over the next five years
- The two leading global therapy areas — oncology and immunology — are forecast to grow 9 12% CAGR through 2025, followed by significant increase in new treatments and medicine use
- Biopharma companies will continue to focus on global market growth, strengthening R&D, and transformation of digital and IT.
The pharmerging markets are expected to witness the fastest growth in the next few years due to a huge customer base, an increase in healthcare expenditure, disease incidence, and the presence of supportive regulatory systems. The region is also fast adapting to new technologies and digital transformation. By considering all the above-mentioned opportunities for the pharma sector to grow in the future, Laurus Labs share price target for 2025 is Rs 870.
|Laurus Labs share price target 2025|
Also read: JP Power share price target.
Laurus Labs Share Price Target 2030
According to Precedence Research, the generic drugs market size is projected to be worth around US$ 675.20 billion by the end of 2030. The global generic drugs market is expected to grow at a CAGR of 5.7% over 2021-30; the market was valued at US$ 387.92 billion in 2020.
The global Active Pharmaceutical Ingredient market is expected to grow at a high single-digit CAGR from 2020 to 2027 to reach US$ 364.17 billion by 2027. Increased healthcare expenditure by the urban population and an increase in the geriatric population is influencing the market growth of APIs. The captive API segment, which holds the dominant market share, is anticipated to grow at a significant rate in the coming years owing to the easy availability of raw materials and greater investments by major players to develop manufacturing facilities.
Major companies are also looking to expand their production capabilities. NCE APIs saw a huge growth in 2020 on the back of R&D initiatives for novel drug development and favorable government regulations. The API market is undergoing immense changes due to supply chain disruption by COVID-19. There is an increasing preference to reduce dependence on China for API products.
Being the cost leader in many ARV APIs, Laurus is best placed to garner an attractive market share in ARV APIs and the Finished Dosage Form (FDF) tender market. The ARV portfolio consists of ~12 APIs, covering both 1st line and 2nd line treatment regimens. Large-scale, improved manufacturing processes have been the key factors in making Laurus the preferred API supplier in the ARV segment. At present, Laurus is supplying to 80% of the players who participate in ARV tenders. Being a fully integrated player, Laurus has a natural advantage and a superior margin profile compared to non-integrated players.
As per the report on the Indian Pharmaceutical Industry 2021 by FICCI and EY, during 2020-30, the Indian pharma industry is expected to grow at a CAGR of 12% to reach US$ 130 billion by 2030 from US$ 41.7 billion in 2020. Though the pharmaceutical industry has grown at a CAGR of approximately 13% over the past two decades, the CAGR for the last decade has been 8.5%. The CAGR for the past five years has been 6.2%. Laurus Labs share price target for 2030 is Rs 3,700.
|Laurus Labs share price target 2030|
Also read: Tata Chemicals share price target.
Laurus Labs Share Price Target 2023, 2024, 2025, and 2030 Table
|Year||Laurus Labs Share Price|
|Laurus Labs share price target 2023||Rs 410|
|Laurus Labs share price target 2024||Rs 620|
|Laurus Labs share price target 2025||Rs 870|
|Laurus Labs share price target 2030||Rs 3,700|
To open a free Demat Account with the best broker in India, click here.
Frequenly Asked Questions
What is the future of Laurus Labs?
As per the report on the Indian Pharmaceutical Industry 2021 by FICCI and EY, during 2020-30, the Indian pharma industry is expected to grow at a CAGR of 12% to reach US$ 130 billion by 2030 from US$ 41.7. As the Indian pharmaceutical industry grows, Laurus Labs will also grow. Therefore, Laurus Labs has a lot of opportunities to grow its business in the future
How good is Laurus Labs share?
Laurus Labs is a very strong company in terms of financials and fundamentals. Laurus Labs has shown a good profit growth of 76% over the past 3 years, good revenue growth of 33% for the past 3 years, maintaining a healthy ROE of 21% over the past 3 years, and also maintaining a healthy ROCE of 20% over the past 3 years.
Is Laurus Labs a good buy now?
Yes, you can Laurus Labs anytime, because Laurus Labs is a strong company with good management, fundamentals, and strong financials.
What is the business of Laurus Labs?
Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs. Today, Laurus Labs is one of the leading suppliers of APIs in the ARV therapeutic area for multinational pharmaceutical companies across different parts of the globe.